Search

Your search keyword '"Vanderkelen M"' showing total 18 results
Start Over Author "Vanderkelen M"
18 results on '"Vanderkelen M"'

1. P.054 Long-term safety and efficacy of zilucoplan in myasthenia gravis: additional interim analyses of RAISE-XT

Author

Genge, A, primary, Howard, JF, additional, Freimer, M, additional, Hewamadduma, C, additional, Hussain, Y, additional, Maniaol, A, additional, Mantegazza, R, additional, Smilowski, M, additional, Utsugisawa, K, additional, Vu, T, additional, Weiss, MD, additional, Duda, PW, additional, Boroojerdi, B, additional, Vanderkelen, M, additional, de la Borderie, G, additional, and Leite, MI, additional

Published
2024
Full Text
View/download PDF

2. P273 Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

Author

Farmakidis, C., primary, Leite, M., additional, Bresch, S., additional, Freimer, M., additional, Genge, A., additional, Hewamadduma, C., additional, Hussain, Y., additional, Maniaol, A., additional, Mantegazza, R., additional, Śmiłowski, M., additional, Utsugisawa, K., additional, Vu, T., additional, Duda, P., additional, Boroojerdi, B., additional, Vanderkelen, M., additional, de la Borderie, G., additional, Bloemers, J., additional, and Howard, J., additional

Published
2023
Full Text
View/download PDF

3. The non-perturbative groundstate of Q.C.D and the local composite operator A_mu^2

Author

Verschelde, H., Knecht, K., Van Acoleyen, K., and Vanderkelen, M.

Subjects
High Energy Physics - Theory
Abstract

We investigate the possibility that the dimension 2 condensate A_mu^2 has a non zero non-perturbative value in Yang-Mills theory. We introduce a multiplicatively renormalisable effective potential for this condensate and show through two loop calculations that a non zero condensate is energetically favoured., Comment: 12 pages

Published
2001
Full Text
View/download PDF

5. OP0297 EFFICACY AND SAFETY OF ROMOSOZUMAB AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND MILD-TO-MODERATE CHRONIC KIDNEY DISEASE

Author

Miller, P., primary, Adachi, J., additional, Albergaria, B. H., additional, Cheung, A. M., additional, Chines, A., additional, Gielen, E., additional, Langdahl, B., additional, Miyauchi, A., additional, Oates, M., additional, Reid, I., additional, Ruiz Santiago, N., additional, Vanderkelen, M., additional, Yang, W., additional, and Yu, Z., additional

Published
2020
Full Text
View/download PDF

7. The H1 detector at HERA

Author

Abt, I, Barth, Marie, Coremans, Ghislaine, Dewulf, Jean-Paul, Evrard, E., Favart, Laurent, Huet, Philippe, Johnson, Denis, Marage, Pierre, Moreels, J., Panitch, Arkadi, Roosen, Robert, Sacton, Jean, Van Beek, Guy, Vanderkelen, M., Van Lancker, Luk, Van Mechelen, Pierre, Abt, I, Barth, Marie, Coremans, Ghislaine, Dewulf, Jean-Paul, Evrard, E., Favart, Laurent, Huet, Philippe, Johnson, Denis, Marage, Pierre, Moreels, J., Panitch, Arkadi, Roosen, Robert, Sacton, Jean, Van Beek, Guy, Vanderkelen, M., Van Lancker, Luk, and Van Mechelen, Pierre

Abstract

General aspects of the H1 detector at the electron-proton storage ring HERA as well as technical descriptions of the magnet, luminosity system, trigger, slow-control, data acquisition and off-line data handling are given. The three major components of the detector, the tracking, calorimeter and muon detectors, will be described in a forthcoming article. The present paper describes the detector that was used from 1992 to the end of 1994. After this a major upgrade of some components was undertaken. Some performance figures from luminosity runs at HERA during 1993 and 1994 are given., 0, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1997

9. The H1 detector at HERA

Author

Abt, I., primary, Ahmed, T., additional, Aid, S., additional, Andreev, V., additional, Andrieu, B., additional, Appuhn, R.D., additional, Arnault, C., additional, Arpagaus, M., additional, Babaev, A., additional, Bärwolff, H., additional, Bán, J., additional, Banas, E., additional, Baranov, P., additional, Barrelet, E., additional, Bartel, W., additional, Barth, M., additional, Bassler, U., additional, Basti, F., additional, Baynham, D.E., additional, Baze, J.-M., additional, Beck, G.A., additional, Beck, H.P., additional, Bederede, D., additional, Behrend, H.-J., additional, Beigbeder, C., additional, Belousov, A., additional, Berger, Ch., additional, Bergstein, H., additional, Bernard, R., additional, Bernardi, G., additional, Bernet, R., additional, Bernier, R., additional, Berthon, U., additional, Bertrand-Coremans, G., additional, Besançon, M., additional, Beyer, R., additional, Biasci, J.-C., additional, Biddulph, P., additional, Bidoli, V., additional, Binder, E., additional, Binko, P., additional, Bizot, J.-C., additional, Blobel, V., additional, Blouzon, F., additional, Blume, H., additional, Borras, K., additional, Boudry, V., additional, Bourdarios, C., additional, Brasse, F., additional, Braunschweig, W., additional, Breton, D., additional, Brettel, H., additional, Brisson, V., additional, Bruncko, D., additional, Brune, C., additional, Buchner, U., additional, Büngener, L., additional, Bürger, J., additional, Büsser, F.W., additional, Buniatian, A., additional, Burke, S., additional, Burmeister, P., additional, Busata, A., additional, Buschhorn, G., additional, Campbell, A.J., additional, Carli, T., additional, Charles, F., additional, Charlet, M., additional, Chase, R., additional, Clarke, D., additional, Clegg, A.B., additional, Colombo, M., additional, Commichau, V., additional, Connolly, J.F., additional, Cornett, U., additional, Coughlan, J.A., additional, Courau, A., additional, Cousinou, M.-C., additional, Coutures, Ch., additional, Coville, A., additional, Cozzika, G., additional, Cragg, D.A., additional, Criegee, L., additional, Cronström, H.I., additional, Cunliffe, N.H., additional, Cvach, J., additional, Cyz, A., additional, Dagoret, S., additional, Dainton, J.B., additional, Danilov, M., additional, Dann, A.W.E., additional, Darvill, D., additional, Dau, W.D., additional, David, J., additional, David, M., additional, Day, R.J., additional, Deffur, E., additional, Delcourt, B., additional, Del Buono, L., additional, Descamps, F., additional, Devel, M., additional, Dewulf, J.P., additional, De Roeck, A., additional, Dingus, P., additional, Djidi, K., additional, Dollfus, C., additional, Dowell, J.D., additional, Dreis, H.B., additional, Drescher, A., additional, Dretzler, U., additional, Duboc, J., additional, Ducorps, A., additional, Düllmann, D., additional, Dünger, O., additional, Duhm, H., additional, Dulny, B., additional, Dupont, F., additional, Ebbinghaus, R., additional, Eberle, M., additional, Ebert, J., additional, Ebert, T.R., additional, Eckerlin, G., additional, Edwards, B.W.H., additional, Efremenko, V., additional, Egli, S., additional, Eichenberger, S., additional, Eichler, R., additional, Eisele, F., additional, Eisenhandler, E., additional, Ellis, N.N., additional, Ellison, R.J., additional, Elsen, E., additional, Epifantsev, A., additional, Erdmann, M., additional, Erdmann, W., additional, Ernst, G., additional, Evrard, E., additional, Falley, G., additional, Favart, L., additional, Fedotov, A., additional, Feeken, D., additional, Felst, R., additional, Feltesse, J., additional, Feng, Z.Y., additional, Fensome, I.F., additional, Fent, J., additional, Ferencei, J., additional, Ferrarotto, F., additional, Finke, K., additional, Flamm, K., additional, Flauger, W., additional, Fleischer, M., additional, Flieser, M., additional, Flower, P.S., additional, Flügge, G., additional, Fomenko, A., additional, Fominykh, B., additional, Forbush, M., additional, Formánek, J., additional, Foster, J.M., additional, Franke, G., additional, Fretwurst, E., additional, Fröchtenicht, W., additional, Fuhrmann, P., additional, Gabathuler, E., additional, Gabathuler, K., additional, Gadow, K., additional, Gamerdinger, K., additional, Garvey, J., additional, Gayler, J., additional, Gažo, E., additional, Gellrich, A., additional, Gennis, M., additional, Gensch, U., additional, Genzel, H., additional, Gerhards, R., additional, Geske, K., additional, Giesgen, I., additional, Gillespie, D., additional, Glasgow, W., additional, Godfrey, L., additional, Godlewski, J., additional, Goerlach, U., additional, Goerlich, L., additional, Gogitidze, N., additional, Goldberg, M., additional, Goodall, A.M., additional, Gorelov, I., additional, Goritchev, P., additional, Gosset, L., additional, Grab, C., additional, Grässler, H., additional, Grässler, R., additional, Greenshaw, T., additional, Gregory, C., additional, Greif, H., additional, Grewe, M., additional, Grindhammer, G., additional, Gruber, A., additional, Gruber, C., additional, Günther, S., additional, Haack, J., additional, Haguenauer, M., additional, Haidt, D., additional, Hajduk, L., additional, Hammer, D., additional, Hamon, O., additional, Hampel, M., additional, Handschuh, D., additional, Hangarter, K., additional, Hanlon, E.M., additional, Hapke, M., additional, Harder, U., additional, Harjes, J., additional, Hartz, P., additional, Hatton, P.E., additional, Haydar, R., additional, Haynes, W.J., additional, Heatherington, J., additional, Hedberg, V., additional, Hedgecock, C.R., additional, Heinzelmann, G., additional, Henderson, R.C.W., additional, Henschel, H., additional, Herma, R., additional, Herynek, I., additional, Hildesheim, W., additional, Hill, P., additional, Hill, D.L., additional, Hilton, C.D., additional, Hladký, J., additional, Hoeger, K.C., additional, Hopes, R.B., additional, Horisberger, R., additional, Hrisoho, A., additional, Huber, J., additional, Huet, Ph., additional, Hufnagel, H., additional, Huot, N., additional, Huppert, J.-F., additional, Ibbotson, M., additional, Imbault, D., additional, Itterbeck, H., additional, Jabiol, M.-A., additional, Jacholkowska, A., additional, Jacobsson, C., additional, Jaffré, M., additional, Jansen, T., additional, Jean, P., additional, Jeanjean, J., additional, Jönsson, L., additional, Johannsen, K., additional, Johnson, D.P., additional, Johnson, L., additional, Jovanovic, P., additional, Jung, H., additional, Kalmus, P.I.P., additional, Kant, D., additional, Kantel, G., additional, Karstensen, S., additional, Kasarian, S., additional, Kaschowitz, R., additional, Kasselmann, P., additional, Kathage, U., additional, Kaufmann, H.H., additional, Kemmerling, G., additional, Kenyon, I.R., additional, Kermiche, S., additional, Keuker, C., additional, Kiesling, C., additional, Klein, M., additional, Kleinwort, C., additional, Knies, G., additional, Ko, W., additional, Kobler, T., additional, Koch, J., additional, Köhler, T., additional, Köhne, J., additional, Kolander, M., additional, Kolanoski, H., additional, Kole, F., additional, Koll, J., additional, Kolya, S.D., additional, Koppitz, B., additional, Korbel, V., additional, Korn, M., additional, Kostka, P., additional, Kotelnikov, S.K., additional, Krasny, M.W., additional, Krehbiel, H., additional, Krivan, F., additional, Krücker, D., additional, Krüger, U., additional, Krüner-Marquis, U., additional, Kubantsev, M., additional, Kubenka, J.P., additional, Külper, T., additional, Küsel, H.-J., additional, Küster, H., additional, Kuhlen, M., additional, Kurča, T., additional, Kurzhöfer, J., additional, Kuznik, B., additional, Laforge, B., additional, Lamarche, F., additional, Lander, R., additional, Landon, M.P.J., additional, Lange, W., additional, Langkau, R., additional, Lanius, P., additional, Laporte, J.-F., additional, Laptin, L., additional, Laskus, H., additional, Lebedev, A., additional, Lemler, M., additional, Lenhardt, U., additional, Leuschner, A., additional, Leverenz, C., additional, Levonian, S., additional, Lewin, D., additional, Ley, Ch., additional, Lindner, A., additional, Lindström, G., additional, Linsel, F., additional, Lipinski, J., additional, Liss, B., additional, Loch, P., additional, Lodge, A.B., additional, Lohmander, H., additional, Lopez, G.C., additional, Lottin, J.-P., additional, Lubimov, V., additional, Ludwig, K., additional, Lüers, D., additional, Lugetski, N., additional, Lundberg, B., additional, Maeshima, K., additional, Magnussen, N., additional, Malinovski, E., additional, Mani, S., additional, Marage, P., additional, Marks, J., additional, Marshall, R., additional, Martens, J., additional, Martin, F., additional, Martin, G., additional, Martin, R., additional, Martyn, H.-U., additional, Martyniak, J., additional, Masbender, V., additional, Masson, S., additional, Mavroidis, A., additional, Maxfield, S.J., additional, McMahon, S.J., additional, Mehta, A., additional, Meier, K., additional, Meissner, J., additional, Mercer, D., additional, Merz, T., additional, Meyer, C.A., additional, Meyer, H., additional, Meyer, J., additional, Mikocki, S., additional, Mills, J.L., additional, Milone, V., additional, Möck, J., additional, Monnier, E., additional, Montés, B., additional, Moreau, F., additional, Moreels, J., additional, Morgan, B., additional, Morris, J.V., additional, Morton, J.M., additional, Müller, K., additional, Murín, P., additional, Murray, S.A., additional, Nagovizin, V., additional, Naroska, B., additional, Naumann, Th., additional, Nayman, P., additional, Nepeipivo, A., additional, Newman, P., additional, Newman-Coburn, D., additional, Newton, D., additional, Neyret, D., additional, Nguyen, H.K., additional, Niebergall, F., additional, Niebuhr, C., additional, Nisius, R., additional, Novák, T., additional, Nováková, H., additional, Nowak, G., additional, Noyes, G.W., additional, Nyberg, M., additional, Oberlack, H., additional, Obrock, U., additional, Olsson, J.E., additional, Olszowska, J., additional, Orenstein, S., additional, Ould-Saada, F., additional, Pailler, P., additional, Palanque, S., additional, Panaro, E., additional, Panitch, A., additional, Parey, J.-Y., additional, Pascaud, C., additional, Patel, G.D., additional, Patoux, A., additional, Paulot, C., additional, Pein, U., additional, Peppel, E., additional, Perez, E., additional, Perrodo, P., additional, Perus, A., additional, Peters, S., additional, Pharabod, J.-P., additional, Phillips, H.T., additional, Phillips, J.P., additional, Pichler, Ch., additional, Pieuchot, A., additional, Pimpl, W., additional, Pitzl, D., additional, Porrovecchio, A., additional, Prell, S., additional, Prosi, R., additional, Quehl, H., additional, Rädel, G., additional, Raupach, F., additional, Rauschnabel, K., additional, Reboux, A., additional, Reimer, P., additional, Reinmuth, G., additional, Reinshagen, S., additional, Ribarics, P., additional, Riech, V., additional, Riedlberger, J., additional, Riege, H., additional, Riess, S., additional, Rietz, M., additional, Robertson, S.M., additional, Robmann, P., additional, Röpnack, P., additional, Roosen, R., additional, Rosenbauer, K., additional, Rostovtsev, A., additional, Royon, C., additional, Rudge, A., additional, Rüter, K., additional, Rudowicz, M., additional, Ruffer, M., additional, Rusakov, S., additional, Rusinov, V., additional, Rybicki, K., additional, Sacton, J., additional, Sahlmann, N., additional, Sanchez, E., additional, Sankey, D.P.C., additional, Savitski, M., additional, Schacht, P., additional, Schiek, S., additional, Schirm, N., additional, Schleif, S., additional, Schleper, P., additional, von Schlippe, W., additional, Schmidt, C., additional, Schmidt, D., additional, Schmidt, G., additional, Schmitz, W., additional, Schmücker, H., additional, Schröder, V., additional, Schütt, J., additional, Schuhmann, E., additional, Schulz, M., additional, Schwind, A., additional, Scobel, W., additional, Seehausen, U., additional, Sefkow, F., additional, Sell, R., additional, Seman, M., additional, Semenov, A., additional, Shatalov, P., additional, Shekelyan, V., additional, Sheviakov, I., additional, Shooshtari, H., additional, Shtarkov, L.N., additional, Siegmon, G., additional, Siewert, U., additional, Sirois, Y., additional, Sirous, A., additional, Skillicorn, I.O., additional, Škvařil, P., additional, Smirnov, P., additional, Smith, J.R., additional, Smolik, L., additional, Sole, D., additional, Soloviev, Y., additional, Špalek, J., additional, Spitzer, H., additional, von Staa, R., additional, Staeck, J., additional, Staroba, P., additional, Šťastný, J., additional, Steenbock, M., additional, Štefan, P., additional, Steffen, P., additional, Steinberg, R., additional, Steiner, H., additional, Stella, B., additional, Stephens, K., additional, Stier, J., additional, Stiewe, J., additional, Stösslein, U., additional, Strachota, J., additional, Straumann, U., additional, Strowbridge, A., additional, Struczinski, W., additional, Sutton, J.P., additional, Szkutnik, Z., additional, Tappern, G., additional, Tapprogge, S., additional, Taylor, R.E., additional, Tchernyshov, V., additional, Tchudakov, V., additional, Thiebaux, C., additional, Thiele, K., additional, Thompson, G., additional, Thompson, R.J., additional, Tichomirov, I., additional, Trenkel, C., additional, Tribanek, W., additional, Tröger, K., additional, Truöl, P., additional, Turiot, M., additional, Turnau, J., additional, Tutas, J., additional, Urban, L., additional, Urban, M., additional, Usik, A., additional, Valkár, Š., additional, Valkárová, A., additional, Vallée, C., additional, Van Beek, G., additional, Vanderkelen, M., additional, Van Lancker, L., additional, Van Mechelen, P., additional, Vartapetian, A., additional, Vazdik, Y., additional, Vecko, M., additional, Verrecchia, P., additional, Vick, R., additional, Villet, G., additional, Vogel, E., additional, Wacker, K., additional, Wagener, M., additional, Walker, I.W., additional, Walther, A., additional, Weber, G., additional, Wegener, D., additional, Wegner, A., additional, Weissbach, P., additional, Wellisch, H.P., additional, West, L., additional, White, D., additional, Willard, S., additional, Winde, M., additional, Winter, G.-G., additional, Wolff, Th., additional, Womersley, L.A., additional, Wright, A.E., additional, Wünsch, E., additional, Wulff, N., additional, Wyborn, B.E., additional, Yiou, T.P., additional, Žáček, J., additional, Zarbock, D., additional, Závada, P., additional, Zeitnitz, C., additional, Zhang, Z., additional, Ziaeepour, H., additional, Zimmer, M., additional, Zimmermann, W., additional, Zomer, F., additional, and Zuber, K., additional

Published
1997
Full Text
View/download PDF

10. The tracking, calorimeter and muon detectors of the H1 experiment at HERA

Author

Abt, I., primary, Ahmed, T., additional, Aid, S., additional, Andreev, V., additional, Andrieu, B., additional, Appuhn, R.-D., additional, Arnault, C., additional, Arpagaus, M., additional, Babaev, A., additional, Bärwolff, H., additional, Bán, J., additional, Banas, E., additional, Baranov, P., additional, Barrelet, E., additional, Bartel, W., additional, Barth, M., additional, Bassler, U., additional, Basti, F., additional, Baynham, D.E., additional, Baze, J.-M., additional, Beck, G.A., additional, Beck, H.P., additional, Bederede, D., additional, Behrend, H.-J., additional, Beigbeder, C., additional, Belousov, A., additional, Berger, Ch., additional, Bergstein, H., additional, Bernard, R., additional, Bernardi, G., additional, Bernet, R., additional, Bernier, R., additional, Berthon, U., additional, Bertrand-Coremans, G., additional, Besançon, M., additional, Beyer, R., additional, Biasci, J.-C., additional, Biddulph, P., additional, Bidoli, V., additional, Binder, E., additional, Binko, P., additional, Bizot, J.-C., additional, Blobel, V., additional, Blouzon, F., additional, Blume, H., additional, Borras, K., additional, Boudry, V., additional, Bourdarios, C., additional, Brasse, F., additional, Braunschweig, W., additional, Breton, D., additional, Brettel, H., additional, Brisson, V., additional, Bruncko, D., additional, Brune, C., additional, Buchner, U., additional, Büngener, L., additional, Bürger, J., additional, Büsser, F.W., additional, Buniatian, A., additional, Burke, S., additional, Burmeister, P., additional, Busata, A., additional, Buschhorn, G., additional, Campbell, A.J., additional, Carli, T., additional, Charles, F., additional, Charlet, M., additional, Chase, R., additional, Clarke, D., additional, Clegg, A.B., additional, Colombo, M., additional, Commichau, V., additional, Connolly, J.F., additional, Cornett, U., additional, Coughlan, J.A., additional, Courau, A., additional, Cousinou, M.-C., additional, Coutures, Ch., additional, Coville, A., additional, Cozzika, G., additional, Cragg, D.A., additional, Criegee, L., additional, Cronström, H.I., additional, Cunliffe, N.H., additional, Cvach, J., additional, Cyz, A., additional, Dagoret, S., additional, Dainton, J.B., additional, Danilov, M., additional, Dann, A.W.E., additional, Darvill, D., additional, Dau, W.D., additional, David, J., additional, David, M., additional, Day, R.J., additional, Deffur, E., additional, Delcourt, B., additional, Del Buono, L., additional, Descamps, F., additional, Devel, M., additional, Dewulf, J.P., additional, De Roeck, A., additional, Dingus, P., additional, Djiki, K., additional, Dollfus, C., additional, Dowell, J.D., additional, Dreis, H.B., additional, Drescher, A., additional, Dretzler, U., additional, Duboc, J., additional, Ducorps, A., additional, Düllmann, D., additional, Dünger, O., additional, Duhm, H., additional, Dulny, B., additional, Dupont, F., additional, Ebbinghaus, R., additional, Eberle, M., additional, Ebert, J., additional, Ebert, T.R., additional, Eckerlin, G., additional, Edwards, B.W.H., additional, Efremenko, V., additional, Egli, S., additional, Eichenberger, S., additional, Eichler, R., additional, Eisele, F., additional, Eisenhandler, E., additional, Ellis, N.N., additional, Ellison, R.J., additional, Elsen, E., additional, Epifantsev, A., additional, Erdmann, M., additional, Erdmann, W., additional, Ernst, G., additional, Evrard, E., additional, Falley, G., additional, Favart, L., additional, Fedotov, A., additional, Feeken, D., additional, Felst, R., additional, Feltesse, J., additional, Feng, Z.Y., additional, Fensome, I.F., additional, Fent, J., additional, Ferencei, J., additional, Ferrarotto, F., additional, Finke, K., additional, Flamm, K., additional, Flauger, W., additional, Fleischer, M., additional, Flieser, M., additional, Flower, P.S., additional, Flügge, G., additional, Fomenko, A., additional, Fominykh, B., additional, Forbush, M., additional, Formánek, J., additional, Foster, J.M., additional, Franke, G., additional, Fretwurst, E., additional, Fröchtenicht, W., additional, Fuhrmann, P., additional, Gabathuler, E., additional, Gabathuler, K., additional, Gadow, K., additional, Gamerdinger, K., additional, Garvey, J., additional, Gayler, J., additional, Gažo, E., additional, Gellrich, A., additional, Gennis, M., additional, Gensch, U., additional, Genzel, H., additional, Gerhards, R., additional, Geske, K., additional, Giesgen, I., additional, Gillespie, D., additional, Glasgow, W., additional, Godfrey, L., additional, Godlewski, J., additional, Goerlach, U., additional, Goerlich, L., additional, Gogitidze, N., additional, Goldberg, M., additional, Goodall, A.M., additional, Gorelov, I., additional, Goritchev, P., additional, Gosset, L., additional, Grab, C., additional, Grässler, H., additional, Grässler, R., additional, Greenshaw, T., additional, Gregory, C., additional, Greif, H., additional, Grewe, M., additional, Grindhammer, G., additional, Gruber, A., additional, Gruber, C., additional, Günther, S., additional, Haack, J., additional, Haguenauer, M., additional, Haidt, D., additional, Hajduk, L., additional, Hammer, D., additional, Hamon, O., additional, Hampel, M., additional, Handschuh, D., additional, Hangarter, K., additional, Hanlon, E.M., additional, Hapke, M., additional, Harder, U., additional, Harjes, J., additional, Hartz, P., additional, Hatton, P.E., additional, Haydar, R., additional, Haynes, W.J., additional, Heatherington, J., additional, Hedberg, V., additional, Hedgecock, C.R., additional, Heinzelmann, G., additional, Henderson, R.C.W., additional, Henschel, H., additional, Herma, R., additional, Herynek, I., additional, Hildesheim, W., additional, Hill, P., additional, Hill, D.L., additional, Hilton, C.D., additional, Hladký, J., additional, Hoeger, K.C., additional, Hopes, R.B., additional, Horisberger, R., additional, Hrisoho, A., additional, Huber, J., additional, Huet, Ph., additional, Hufnagel, H., additional, Huot, N., additional, Huppert, J.-F., additional, Ibbotson, M., additional, Imbault, D., additional, Itterbeck, H., additional, Jabiol, M.-A., additional, Jacholkowska, A., additional, Jacobsson, C., additional, Jaffré, M., additional, Janoth, J., additional, Jansen, T., additional, Jean, P., additional, Jeanjean, J., additional, Jönsson, L., additional, Johannsen, K., additional, Johnson, D.P., additional, Johnson, L., additional, Jovanovic, P., additional, Jung, H., additional, Kalmus, P.I.P., additional, Kant, D., additional, Kantel, G., additional, Karstensen, S., additional, Kasarian, S., additional, Kaschowitz, R., additional, Kasselmann, P., additional, Kathage, U., additional, Kaufmann, H.H., additional, Kemmerling, G., additional, Kenyon, I.R., additional, Kermiche, S., additional, Keuker, C., additional, Kiesling, C., additional, Klein, M., additional, Kleinwort, C., additional, Knies, G., additional, Ko, W., additional, Kobler, T., additional, Koch, J., additional, Köhler, T., additional, Köhne, J., additional, Kolander, M., additional, Kolanoski, H., additional, Kole, F., additional, Koll, J., additional, Kolya, S.D., additional, Koppitz, B., additional, Korbel, V., additional, Korn, M., additional, Kostka, P., additional, Kotelnikov, S.K., additional, Krasny, M.W., additional, Krehbiel, H., additional, Krivan, F., additional, Krücker, D., additional, Krüger, U., additional, Krüner-Marquis, U., additional, Kubantsev, M., additional, Kubenka, J.P., additional, Külper, T., additional, Küsel, H.-J., additional, Küster, H., additional, Kuhlen, M., additional, Kurča, T., additional, Kurzhöfer, J., additional, Kuznik, B., additional, Laforge, B., additional, Lamarche, F., additional, Lander, R., additional, Landon, M.P.J., additional, Lange, W., additional, Langkau, R., additional, Lanius, P., additional, Laporte, J.-F., additional, Laptin, L., additional, Laskus, H., additional, Lebedev, A., additional, Lemler, M., additional, Lenhardt, U., additional, Leuschner, A., additional, Leverenz, C., additional, Levonian, S., additional, Lewin, D., additional, Ley, Ch., additional, Lindner, A., additional, Lindström, G., additional, Linsel, F., additional, Lipinski, J., additional, Liss, B., additional, Loch, P., additional, Lodge, A.B., additional, Lohmander, H., additional, Lopez, G.C., additional, Lottin, J.-P., additional, Lubimov, V., additional, Ludwig, K., additional, Lüers, D., additional, Lugetski, N., additional, Lundberg, B., additional, Maeshima, K., additional, Magnussen, N., additional, Malinovski, E., additional, Mani, S., additional, Marage, P., additional, Marks, J., additional, Marshall, R., additional, Martens, J., additional, Martin, F., additional, Martin, G., additional, Martin, R., additional, Martyn, H.-U., additional, Martyniak, J., additional, Masbender, V., additional, Masson, S., additional, Mavroidis, A., additional, Maxfield, S.J., additional, McMahon, S.J., additional, Mehta, A., additional, Meier, K., additional, Meissner, J., additional, Mercer, D., additional, Merz, T., additional, Meyer, C.A., additional, Meyer, H., additional, Meyer, J., additional, Mikocki, S., additional, Mills, J.L., additional, Milone, V., additional, Möck, J., additional, Monnier, E., additional, Montés, B., additional, Moreau, F., additional, Moreels, J., additional, Morgan, B., additional, Morris, J.V., additional, Morton, J.M., additional, Müller, K., additional, Murín, P., additional, Murray, S.A., additional, Nagovizin, V., additional, Naroska, B., additional, Naumann, Th., additional, Nayman, P., additional, Nepeipivo, A., additional, Newman, P., additional, Newman-Coburn, D., additional, Newton, D., additional, Neyret, D., additional, Nguyen, H.K., additional, Niebergall, F., additional, Niebuhr, C., additional, Nisius, R., additional, Novák, T., additional, Nováková, H., additional, Nowak, G., additional, Noyes, G.W., additional, Nyberg, M., additional, Oberlack, H., additional, Obrock, U., additional, Olsson, J.E., additional, Olszowska, J., additional, Orenstein, S., additional, Ould-Saada, F., additional, Pailler, P., additional, Palanque, S., additional, Panaro, E., additional, Panitch, A., additional, Parey, J.-Y., additional, Pascaud, C., additional, Patel, G.D., additional, Patoux, A., additional, Paulot, C., additional, Pein, U., additional, Peppel, E., additional, Perez, E., additional, Perrodo, P., additional, Perus, A., additional, Peters, S., additional, Pharabod, J.-P., additional, Phillips, H.T., additional, Phillips, J.P., additional, Pichler, Ch., additional, Pieuchot, A., additional, Pimpl, W., additional, Pitzl, D., additional, Porrovecchio, A., additional, Prell, S., additional, Prosi, R., additional, Quehl, H., additional, Rädel, G., additional, Raupach, F., additional, Rauschnabel, K., additional, Reboux, A., additional, Reimer, P., additional, Reinmuth, G., additional, Reinshagen, S., additional, Ribarics, P., additional, Riech, V., additional, Riedlberger, J., additional, Riege, H., additional, Riess, S., additional, Rietz, M., additional, Robertson, S.M., additional, Robmann, P., additional, Röpnack, P., additional, Roosen, R., additional, Rosenbauer, K., additional, Rostovtsev, A., additional, Royon, C., additional, Rudge, A., additional, Rüter, K., additional, Rudowicz, M., additional, Ruffer, M., additional, Rusakov, S., additional, Rusinov, V., additional, Rybicki, K., additional, Sacton, J., additional, Sahlmann, N., additional, Sanchez, E., additional, Sankey, D.P.C., additional, Savitski, M., additional, Schacht, P., additional, Schiek, S., additional, Schirm, N., additional, Schleif, S., additional, Schleper, P., additional, von Schlippe, W., additional, Schmidt, C., additional, Schmidt, D., additional, Schmidt, G., additional, Schmitz, W., additional, Schmücker, H., additional, Schröder, V., additional, Schütt, J., additional, Schuhmann, E., additional, Schulz, M., additional, Schwind, A., additional, Scobel, W., additional, Seehausen, U., additional, Sefkow, F., additional, Sell, R., additional, Seman, M., additional, Semenov, A., additional, Shatalov, P., additional, Shekelyan, V., additional, Sheviakov, I., additional, Shooshtari, H., additional, Shtarkov, L.N., additional, Siegmon, G., additional, Siewert, U., additional, Sirois, Y., additional, Sirous, A., additional, Skillicorn, I.O., additional, Škvařil, P., additional, Smirnov, P., additional, Smith, J.R., additional, Smolik, L., additional, Sole, D., additional, Soloviev, Y., additional, Špalek, J., additional, Spitzer, H., additional, von Staa, R., additional, Staeck, J., additional, Staroba, P., additional, Šťastný, J., additional, Steenbock, M., additional, Štefan, P., additional, Steffen, P., additional, Steinberg, R., additional, Steiner, H., additional, Stella, B., additional, Stephens, K., additional, Stier, J., additional, Stiewe, J., additional, Stösslein, U., additional, Strachota, J., additional, Straumann, U., additional, Strowbridge, A., additional, Struczinski, W., additional, Sutton, J.P., additional, Szkutnik, Z., additional, Tappern, G., additional, Tapprogge, S., additional, Taylor, R.E., additional, Tchernyshov, V., additional, Tchudakov, V., additional, Thiebaux, C., additional, Thiele, K., additional, Thompson, G., additional, Thompson, R.J., additional, Tichomirov, I., additional, Trenkel, C., additional, Tribanek, W., additional, Tröger, K., additional, Truöl, P., additional, Turiot, M., additional, Turnau, J., additional, Tutas, J., additional, Urban, L., additional, Urban, M., additional, Usik, A., additional, Valkár, Š., additional, Valkárová, A., additional, Vallée, C., additional, Van Beek, G., additional, Vanderkelen, M., additional, Van Lancker, L., additional, Van Mechelen, P., additional, Vartapetian, A., additional, Vazdik, Y., additional, Vecko, M., additional, Verrecchia, P., additional, Vick, R., additional, Villet, G., additional, Vogel, E., additional, Wacker, K., additional, Wagener, M., additional, Walker, I.W., additional, Walther, A., additional, Weber, G., additional, Wegener, D., additional, Wegner, A., additional, Weissbach, P., additional, Wellisch, H.P., additional, West, L., additional, White, D., additional, Willard, S., additional, Winde, M., additional, Winter, G.-G., additional, Wolff, Th., additional, Womersley, L.A., additional, Wright, A.E., additional, Wünsch, E., additional, Wulff, N., additional, Wyborn, B.E., additional, Yiou, T.P., additional, Žáček, J., additional, Zarbock, D., additional, Závada, P., additional, Zeitnitz, C., additional, Zhang, Z., additional, Ziaeepour, H., additional, Zimmer, M., additional, Zimmermann, W., additional, Zomer, F., additional, and Zuber, K., additional

Published
1997
Full Text
View/download PDF

11. The H1 detector at HERA

Author

Abt, I., Ahmed, T., Aid, S., Andreev, V., Andrieu, B., Appuhn, R D., Arnault, C., Arpagaus, M., Babaev, A., Brwolff, H., Bn, J., Banas, E., Baranov, P., Barrelet, E., Bartel, W., Bassler, U., Basti, F., Baynham, D E., Baze, J M., Beck, G A., Beck, H P., Bederede, D., Behrend, H J., Beigbeder, C., Belousov, A., Berger, C., Bergstein, H., Bernard, R., Bernardi, G., Bernet, R., Bernier, R., Berthon, U., Bertrand-Coremans, G., Besanon, M., Beyer, R., Biasci, J C., Biddulph, P., Bidoli, V., Binder, E., Binko, P., Bizot, J C., Blobel, V., Blouzon, F., Blume, H., Borras, K., Boudry, V., Bourdarios, C., Brasse, F., Braunschweig, W., Breton, D., Brettel, H., Brisson, V., Bruncko, D., Brune, C., Buchner, U., Bngener, L., Brger, J., Bsser, F W., Buniatian, A., Burke, S., Burmeister, P., Busata, A., Buschhorn, G., Campbell, A J., Carli, T., Charles, F., Charlet, M., Chase, R L., Clarke, D., Clegg, A B., Colombo, M., Commichau, V., Connolly, J F., Cornett, U., Coughlan, J A., Courau, A., Cousinou, M C., Coutures, C., Coville, A., Cozzika, G., Cragg, D A., Criegee, L., Cronstrm, H I., Cunliffe, N H., Cyz, A., Dagoret, S., Dainton, J B., Danilov, M., Dann, A W E., Darvill, D., Dau, W D., David, J., David, M., Day, R J., Deffur, E., Delcourt, B., Del Buono, L., Deschamps, F., Devel, M., DeWulf, J P., de Roeck, A., Dingus, P., Djidi, K., Dollfus, C., Dowell, J D., Dreis, H B., Drescher, A., Dretzler, U., Duboc, J., Ducorps, A., Dllmann, D., Dnger, O., Duhm, H., Dulny, B., Dupont, J., Ebbinghaus, R., Eberle, M., Ebert, J., Ebert, T R., Eckerlin, G., Edwards, B W H., Efremenko, V., Egli, S., Eichenberger, S., Eichler, R., Eisele, F., Eisenhandler, E., Ellis, N N., Ellison, R J., Elsen, E., Epifantsev, A., Erdmann, M., Erdmann, W., Ernst, G., Evrard, E., Falley, G., Fedotov, A., Feeken, D., Felst, R., Feltesse, J., Feng, Z Y., Fensome, I F., Fent, J., Ferencei, J., Ferrarotto, F., Finke, K., Flamm, K., Flauger, W., Fleischer, M., Flieser, M., Flower, P S., Flgge, G., Fomenko, A., Forbush, M., Formnek, J., Foster, J M., Franke, G., Fretwurst, E., Frchtenicht, W., Fuhrmann, P., Gabathuler, E., Gabathuler, K., Gadow, K., Gamerdinger, K., Garvey, J., Gayler, J., Gazo, E., Gennis, M., Gensch, U., Genzel, H., Gerhards, R., Geske, K., Giesgen, I., Gillespie, D., Godfrey, L., Godlewski, J., Goerlach, U., Goerlich, L., Gogitidze, N., Goldberg, M., Goodall, A M., Gorelov, I., Goritchev, P., Gosset, L., Grab, C., Grssler, H., Grssler, R., Greenshaw, T., Gregory, C., Greif, H., Grewe, M., Grindhammer, G., Gruber, A., Gruber, C., Gnther, S., Haack, J., Haguenauer, M., Haidt, D., Hajduk, L., Hammer, D., Hamon, O., Handschuh, D., Hangarter, K., Hanlon, E M., Harder, U., Harjes, J., Hartz, P., Hatton, P E., Haydar, R., Haynes, W J., Heatherington, J., Hedberg, V., Hedgecock, C R., Heinzelmann, G., Henderson, R C W., Henschel, H., Herma, R., Herynek, I., Hildesheim, W., Hill, P., Hill, D L., Hilton, C D., Hladky, J., Hoeger, K C., Hopes, R B., Horisberger, R., Hrisoho, A., Huber, J., Huet, P., Hufnagel, H., Huot, N., Huppert, J F., Ibbotson, M., Imbault, D., Itterbeck, H., Jabiol, M A., Jacholkowska, A., Jacobsson, C., Jaffr, M., Janoth, J., Jansen, T., Jean, P., Jeanjean, J., Jnsson, L., Johannsen, K., Johnson, D P., Johnson, L., Jovanovic, P., Jung, H., Kalmus, P I P., Kant, D., Kantel, G., Karstensen, S., Kasarian, S., Kaschowitz, R., Kasselmann, P., Kathage, U., Kaufmann, H H., Kemmerling, G., Kenyon, I R., Kermiche, S., Keuker, C., Kiesling, C., Klein, M., Kleinwort, C., Knies, G., Ko, W., Kobler, T., Koch, J., Khler, T., Kolander, M., Kolanoski, H., Kole, F., Koll, J., Kolya, S D., Koppitz, B., Korbel, V., Korn, M., Kostka, P., Kotelnikov, S K., Krasny, MW., Krehbiel, H., Krivan, F., Krcker, D., Krger, U., Krner-Marquis, U., Kubantsev, M., Kubenka, J P., Klper, T., Kssel, H J., Kster, H., Kuhlen, M., Kurca, T., Kurzhfer, J., Kuznik, B., Laforge, B., Lamarche, F., Lander, R., Landon, M P J., Lange, W., Langkau, R., Lanius, P., Laporte, J F., Laptin, L., Laskus, H., Lebedev, A., Lemler, M., Lenhardt, U., Leuschner, A., Leverenz, C., Levonian, S., Ley, C., Lindner, A., Lindstrm, G., Linsel, F., Lipinski, J., Liss, B., Loch, P., Lodge, A B., Lohmander, H., Lopez, G C., Lottin, J P., Lubimov, V., Ludwig, K., Lers, D., Lugetski, N., Lundberg, B., Maeshima, K., Magnussen, N., Malinovski, E., Mani, S., Marage, P., Marks, J., Marshall, R., Martens, J., Martin, F., Martin, G., Martin, R., Martyn, H U., Martyniak, J., Masbender, V., Masson, S., Mavroidis, A., Maxfield, S J., McMahon, S J., Mehta, A., Meier, K., Meissner, J., Mercer, D., Merz, T., Meyer, C A., Meyer, H., Meyer, J., Mikocki, S., Mills, J L., Milone, V., Mck, J., Monnier, E., Moreau, F., Moreels, J., Morgan, B., Morris, J V., Morton, J M., Mller, K., Murn, P., Murray, S A., Nagovitsin, V., Naroska, B., Naumann, T., Nayman, P., Nepeipivo, A., Newman-Coburn, D., Neyret, D., Nguyen, H K., Niebergall, F., Niebuhr, C., Nisius, R., Novk, T., Novkova, H., Noyes, G W., Nyberg, M., Oberlack, H., Obrock, U., Olsson, J E., Olszowska, J., Orenstein, S., Ould-Saada, F., Pailler, P., Palanque, S., Panaro, E., Panitch, A., Parey, J Y., Pascaud, C., Patel, G D., Patoux, A., Paulot, C., Pein, U., Peppel, E., Prez, E., Perrodo, P., Perus, A., Peters, S., Pharabod, J P., Phillips, H T., Phillips, J P., Pichler, C., Pieuchot, A., Pimpl, W., Pitzl, D., Porrovecchio, A., Prell, S., Prosi, R., Quehl, H., Rdel, G., Raupach, F., Rauschnabel, K., Reboux, A., Reimer, P., Reinmuth, G., Reinshagen, S., Ribarics, P., Riech, V., Riedlberger, J., Riege, H., Riess, S., Rietz, M., Robertson, S M., Robmann, P., Rpnack, P., Roosen, R., Rostovtsev, A., Royon, C., Rudge, A., Rudowicz, M., Ruffer, M., Rusakov, S., Rusinov, V., Rybicki, K., Sacton, J., Sahlmann, N., Snchez, E., Sankey DP, C., Savitski, M., Schacht, P., Schiek, S., Schirm, N., Scheif, S., Schleper, P., von Schlippe, W., Schmidt, C., Schmidt, D., Schmidt, G., Schmitz, W., Schmcker, H., Schrder, V., Schtt, J., Schulz, M., Schwind, A., Scobel, W., Seehausen, U., Sefkow, F., Sell, R., Seman, M., Semenov, A., Shatalov, P., Shekelyan, V., Sheviakov, I., Shooshtari, H., Shtarkov, L N., Siegmon, G., Siewert, U., Sirois, Y., Sirous, A., Skillicorn, I O., Skvaril, P., Smirnov, P., Smith, J R., Smolik, L., Sole, D., Spalek, J., Spitzer, H., Von Staa, R., Staeck, J., Staroba, P., Stastny, J., Steenbock, M., Stefan, P., Steffen, P., Steinberg, R., Steiner, H., Stella, B., Stephens, K., Stier, J., Stiewe, J., Stsslein, U., Strachota, J., Straumann, U., Strowbridge, A., Struczinski, W., Sutton, J P., Szkutnik, Z., Tappern, G J., Tapprogge, S., Taylor, R E., Tchernyshov, V., Tchudakov, V., Thiebaux, C., Thiele, K., Thompson, G., Thompson, R J., Tichomirov, I., Trenkel, C., Tribanek, W., Trger, K., Trul, P., Turiot, M., Turnau, J., Tutas, J., Urbn, L., Urban, M., Usik, A., Valkr, S., Valkrov, A., Vallee, C., Van Beek, G., Vanderkelen, M., Van Lancker, L., Vartapetian, A., Vazdik, Y., Vecko, M., Verrecchia, P., Vick, R., Villet, G., Vogel, E., Wacker, K., Wagener, M., Walker, I W., Walther, A., Weber, G., Wegener, D., Wegner, A., Weissbach, P., Wellisch, H P., West, L., White, D., Willard, S., Winde, M., Winter, G G., Wolff, M T., Womersley, L A., Wright, A E., Wnsch, E., Wulff, N., Wyborn, B E., Yiou, T P., Zcek, J., Zarbock, D., Zvada, P., Zeitnitz, C., Zhang, Z., Ziaeepour, H., Zimmer, M., Zimmermann, W., Zomer, F., Zuber, K., Abt, I., Ahmed, T., Aid, S., Andreev, V., Andrieu, B., Appuhn, R D., Arnault, C., Arpagaus, M., Babaev, A., Brwolff, H., Bn, J., Banas, E., Baranov, P., Barrelet, E., Bartel, W., Bassler, U., Basti, F., Baynham, D E., Baze, J M., Beck, G A., Beck, H P., Bederede, D., Behrend, H J., Beigbeder, C., Belousov, A., Berger, C., Bergstein, H., Bernard, R., Bernardi, G., Bernet, R., Bernier, R., Berthon, U., Bertrand-Coremans, G., Besanon, M., Beyer, R., Biasci, J C., Biddulph, P., Bidoli, V., Binder, E., Binko, P., Bizot, J C., Blobel, V., Blouzon, F., Blume, H., Borras, K., Boudry, V., Bourdarios, C., Brasse, F., Braunschweig, W., Breton, D., Brettel, H., Brisson, V., Bruncko, D., Brune, C., Buchner, U., Bngener, L., Brger, J., Bsser, F W., Buniatian, A., Burke, S., Burmeister, P., Busata, A., Buschhorn, G., Campbell, A J., Carli, T., Charles, F., Charlet, M., Chase, R L., Clarke, D., Clegg, A B., Colombo, M., Commichau, V., Connolly, J F., Cornett, U., Coughlan, J A., Courau, A., Cousinou, M C., Coutures, C., Coville, A., Cozzika, G., Cragg, D A., Criegee, L., Cronstrm, H I., Cunliffe, N H., Cyz, A., Dagoret, S., Dainton, J B., Danilov, M., Dann, A W E., Darvill, D., Dau, W D., David, J., David, M., Day, R J., Deffur, E., Delcourt, B., Del Buono, L., Deschamps, F., Devel, M., DeWulf, J P., de Roeck, A., Dingus, P., Djidi, K., Dollfus, C., Dowell, J D., Dreis, H B., Drescher, A., Dretzler, U., Duboc, J., Ducorps, A., Dllmann, D., Dnger, O., Duhm, H., Dulny, B., Dupont, J., Ebbinghaus, R., Eberle, M., Ebert, J., Ebert, T R., Eckerlin, G., Edwards, B W H., Efremenko, V., Egli, S., Eichenberger, S., Eichler, R., Eisele, F., Eisenhandler, E., Ellis, N N., Ellison, R J., Elsen, E., Epifantsev, A., Erdmann, M., Erdmann, W., Ernst, G., Evrard, E., Falley, G., Fedotov, A., Feeken, D., Felst, R., Feltesse, J., Feng, Z Y., Fensome, I F., Fent, J., Ferencei, J., Ferrarotto, F., Finke, K., Flamm, K., Flauger, W., Fleischer, M., Flieser, M., Flower, P S., Flgge, G., Fomenko, A., Forbush, M., Formnek, J., Foster, J M., Franke, G., Fretwurst, E., Frchtenicht, W., Fuhrmann, P., Gabathuler, E., Gabathuler, K., Gadow, K., Gamerdinger, K., Garvey, J., Gayler, J., Gazo, E., Gennis, M., Gensch, U., Genzel, H., Gerhards, R., Geske, K., Giesgen, I., Gillespie, D., Godfrey, L., Godlewski, J., Goerlach, U., Goerlich, L., Gogitidze, N., Goldberg, M., Goodall, A M., Gorelov, I., Goritchev, P., Gosset, L., Grab, C., Grssler, H., Grssler, R., Greenshaw, T., Gregory, C., Greif, H., Grewe, M., Grindhammer, G., Gruber, A., Gruber, C., Gnther, S., Haack, J., Haguenauer, M., Haidt, D., Hajduk, L., Hammer, D., Hamon, O., Handschuh, D., Hangarter, K., Hanlon, E M., Harder, U., Harjes, J., Hartz, P., Hatton, P E., Haydar, R., Haynes, W J., Heatherington, J., Hedberg, V., Hedgecock, C R., Heinzelmann, G., Henderson, R C W., Henschel, H., Herma, R., Herynek, I., Hildesheim, W., Hill, P., Hill, D L., Hilton, C D., Hladky, J., Hoeger, K C., Hopes, R B., Horisberger, R., Hrisoho, A., Huber, J., Huet, P., Hufnagel, H., Huot, N., Huppert, J F., Ibbotson, M., Imbault, D., Itterbeck, H., Jabiol, M A., Jacholkowska, A., Jacobsson, C., Jaffr, M., Janoth, J., Jansen, T., Jean, P., Jeanjean, J., Jnsson, L., Johannsen, K., Johnson, D P., Johnson, L., Jovanovic, P., Jung, H., Kalmus, P I P., Kant, D., Kantel, G., Karstensen, S., Kasarian, S., Kaschowitz, R., Kasselmann, P., Kathage, U., Kaufmann, H H., Kemmerling, G., Kenyon, I R., Kermiche, S., Keuker, C., Kiesling, C., Klein, M., Kleinwort, C., Knies, G., Ko, W., Kobler, T., Koch, J., Khler, T., Kolander, M., Kolanoski, H., Kole, F., Koll, J., Kolya, S D., Koppitz, B., Korbel, V., Korn, M., Kostka, P., Kotelnikov, S K., Krasny, MW., Krehbiel, H., Krivan, F., Krcker, D., Krger, U., Krner-Marquis, U., Kubantsev, M., Kubenka, J P., Klper, T., Kssel, H J., Kster, H., Kuhlen, M., Kurca, T., Kurzhfer, J., Kuznik, B., Laforge, B., Lamarche, F., Lander, R., Landon, M P J., Lange, W., Langkau, R., Lanius, P., Laporte, J F., Laptin, L., Laskus, H., Lebedev, A., Lemler, M., Lenhardt, U., Leuschner, A., Leverenz, C., Levonian, S., Ley, C., Lindner, A., Lindstrm, G., Linsel, F., Lipinski, J., Liss, B., Loch, P., Lodge, A B., Lohmander, H., Lopez, G C., Lottin, J P., Lubimov, V., Ludwig, K., Lers, D., Lugetski, N., Lundberg, B., Maeshima, K., Magnussen, N., Malinovski, E., Mani, S., Marage, P., Marks, J., Marshall, R., Martens, J., Martin, F., Martin, G., Martin, R., Martyn, H U., Martyniak, J., Masbender, V., Masson, S., Mavroidis, A., Maxfield, S J., McMahon, S J., Mehta, A., Meier, K., Meissner, J., Mercer, D., Merz, T., Meyer, C A., Meyer, H., Meyer, J., Mikocki, S., Mills, J L., Milone, V., Mck, J., Monnier, E., Moreau, F., Moreels, J., Morgan, B., Morris, J V., Morton, J M., Mller, K., Murn, P., Murray, S A., Nagovitsin, V., Naroska, B., Naumann, T., Nayman, P., Nepeipivo, A., Newman-Coburn, D., Neyret, D., Nguyen, H K., Niebergall, F., Niebuhr, C., Nisius, R., Novk, T., Novkova, H., Noyes, G W., Nyberg, M., Oberlack, H., Obrock, U., Olsson, J E., Olszowska, J., Orenstein, S., Ould-Saada, F., Pailler, P., Palanque, S., Panaro, E., Panitch, A., Parey, J Y., Pascaud, C., Patel, G D., Patoux, A., Paulot, C., Pein, U., Peppel, E., Prez, E., Perrodo, P., Perus, A., Peters, S., Pharabod, J P., Phillips, H T., Phillips, J P., Pichler, C., Pieuchot, A., Pimpl, W., Pitzl, D., Porrovecchio, A., Prell, S., Prosi, R., Quehl, H., Rdel, G., Raupach, F., Rauschnabel, K., Reboux, A., Reimer, P., Reinmuth, G., Reinshagen, S., Ribarics, P., Riech, V., Riedlberger, J., Riege, H., Riess, S., Rietz, M., Robertson, S M., Robmann, P., Rpnack, P., Roosen, R., Rostovtsev, A., Royon, C., Rudge, A., Rudowicz, M., Ruffer, M., Rusakov, S., Rusinov, V., Rybicki, K., Sacton, J., Sahlmann, N., Snchez, E., Sankey DP, C., Savitski, M., Schacht, P., Schiek, S., Schirm, N., Scheif, S., Schleper, P., von Schlippe, W., Schmidt, C., Schmidt, D., Schmidt, G., Schmitz, W., Schmcker, H., Schrder, V., Schtt, J., Schulz, M., Schwind, A., Scobel, W., Seehausen, U., Sefkow, F., Sell, R., Seman, M., Semenov, A., Shatalov, P., Shekelyan, V., Sheviakov, I., Shooshtari, H., Shtarkov, L N., Siegmon, G., Siewert, U., Sirois, Y., Sirous, A., Skillicorn, I O., Skvaril, P., Smirnov, P., Smith, J R., Smolik, L., Sole, D., Spalek, J., Spitzer, H., Von Staa, R., Staeck, J., Staroba, P., Stastny, J., Steenbock, M., Stefan, P., Steffen, P., Steinberg, R., Steiner, H., Stella, B., Stephens, K., Stier, J., Stiewe, J., Stsslein, U., Strachota, J., Straumann, U., Strowbridge, A., Struczinski, W., Sutton, J P., Szkutnik, Z., Tappern, G J., Tapprogge, S., Taylor, R E., Tchernyshov, V., Tchudakov, V., Thiebaux, C., Thiele, K., Thompson, G., Thompson, R J., Tichomirov, I., Trenkel, C., Tribanek, W., Trger, K., Trul, P., Turiot, M., Turnau, J., Tutas, J., Urbn, L., Urban, M., Usik, A., Valkr, S., Valkrov, A., Vallee, C., Van Beek, G., Vanderkelen, M., Van Lancker, L., Vartapetian, A., Vazdik, Y., Vecko, M., Verrecchia, P., Vick, R., Villet, G., Vogel, E., Wacker, K., Wagener, M., Walker, I W., Walther, A., Weber, G., Wegener, D., Wegner, A., Weissbach, P., Wellisch, H P., West, L., White, D., Willard, S., Winde, M., Winter, G G., Wolff, M T., Womersley, L A., Wright, A E., Wnsch, E., Wulff, N., Wyborn, B E., Yiou, T P., Zcek, J., Zarbock, D., Zvada, P., Zeitnitz, C., Zhang, Z., Ziaeepour, H., Zimmer, M., Zimmermann, W., Zomer, F., and Zuber, K.

12. Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK.

Author

Abbasi A, Fryk H, Rudnik J, White R, Vanderkelen M, Scowcroft A, and Bonar K

Subjects
Humans, Riluzole therapeutic use, Prevalence, Algorithms, United Kingdom epidemiology, Amyotrophic Lateral Sclerosis diagnosis, Motor Neuron Disease
Abstract

Background: There is an increasing need to better understand the burden of amyotrophic lateral sclerosis (ALS) using real-world data (RWD). However, identifying ALS cases using RWD presents several challenges due to the rarity of ALS and the differences in database coding systems., Methods: MarketScan claims, and the UK Clinical Practice Research Datalink (CPRD) databases were searched for diagnosis codes of ALS or MND, the only drugs approved for treating ALS (riluzole and edaravone) and clinical visits with 12-month enrolment prior to 1 January 2011. The main algorithm required ≥ 1 ALS diagnosis code together with prescriptions or clinical visits. We expanded the existing algorithm to identify unspecific (possible) ALS group that had codes for motor neuron disease (MND) and the ALS drugs. The study period was from 1 January 2011 until 31 December 2020., Results: We identified 16,246 patients with ≥ 1 ALS code in Marketscan (denominator n = 85,279,619), yet only 184 were found in the UK CPRD (denominator n = 21,318,589). Using the main algorithm 9,433 ALS patients were included in MarketScan, with a prevalence ranged between 4.5 per 100,000 in 2019 and 6.2 in 2015. In MarketScan, 3,658 (4.3 per 100,000) had ≥ 1 MND code and the ALS drug codes (possible cases). In CPRD, 47.9% of 2,785 patients with ≥ 1 MND code had a prescription for riluzole (6.3 per 100,000), regarded as possible ALS cases., Conclusions: The expanded algorithm enabled the identification of a large population with ALS, or possible ALS, and the estimation of ALS prevalence in MarketScan and CPRD., (© 2024. Fondazione Società Italiana di Neurologia.)

Published
2024
Full Text
View/download PDF

13. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.

Author

Howard JF Jr, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Nowak RJ, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Bloemers J, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Vanderkelen M, and Leite MI

Abstract

Background: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments., Objectives: To evaluate the long-term safety, tolerability, and efficacy of zilucoplan in a mild-to-severe, acetylcholine receptor autoantibody-positive (AChR+) gMG population., Design: Ongoing, multicenter, phase III open-label extension (OLE) study., Methods: Eligible patients had completed a qualifying randomized, placebo-controlled phase II or phase III zilucoplan study and received daily, self-administered subcutaneous 0.3 mg/kg zilucoplan. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Secondary efficacy endpoints included change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score., Results: In total, 200 patients enrolled. At the cut-off date (8 September 2022), median (range) exposure to zilucoplan in RAISE-XT was 1.2 (0.11-4.45) years. Mean age at OLE baseline was 53.3 years. A total of 188 (94%) patients experienced a TEAE, with the most common being MG worsening ( n  = 52, 26%) and COVID-19 ( n  = 49, 25%). In patients who received zilucoplan 0.3 mg/kg in the parent study, further improvements in MG-ADL score continued through to Week 24 (least squares mean change [95% confidence interval] from double-blind baseline -6.06 [-7.09, -5.03]) and were sustained through to Week 60 (-6.04 [-7.21, -4.87]). In patients who switched from placebo in the parent study, rapid improvements in MG-ADL score were observed at the first week after switching to zilucoplan; further improvements were observed at Week 24, 12 weeks after switching (-6.46 [-8.19, -4.72]), and were sustained through to Week 60 (-6.51 [-8.37, -4.65]). Consistent results were observed in other efficacy endpoints., Conclusion: Zilucoplan demonstrated a favorable long-term safety profile, good tolerability, and sustained efficacy through to Week 60 with consistent benefits in a broad AChR+ gMG population. Additional long-term data will be available in future analyses., Trial Registration: ClinicalTrials.gov identifier: NCT04225871 (https://clinicaltrials.gov/ct2/show/NCT04225871)., (© The Author(s), 2024.)

Published
2024
Full Text
View/download PDF

14. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.

Author

Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, and Leite MI

Subjects
Humans, Activities of Daily Living, Complement C5 therapeutic use, Immunologic Factors therapeutic use, Double-Blind Method, Treatment Outcome, COVID-19, Myasthenia Gravis drug therapy
Abstract

Background: Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare disease, often accompanied by high treatment burden and with an unmet need for more efficacious and well tolerated treatments. Zilucoplan is a subcutaneous, self-administered macrocyclic peptide complement C5 inhibitor. We aimed to assess safety, efficacy, and tolerability of zilucoplan in patients with acetylcholine receptor autoantibody (AChR)-positive generalised myasthenia gravis., Methods: RAISE was a randomised, double-blind, placebo-controlled, phase 3 trial that was done at 75 sites in Europe, Japan, and North America. We enrolled patients (aged 18-74 years) with AChR-positive generalised myasthenia gravis (Myasthenia Gravis Foundation of America disease class II-IV), a myasthenia gravis activities of daily living (MG-ADL) score of least 6, and a quantitative myasthenia gravis score of at least 12. Participants were randomly assigned (1:1) to receive subcutaneous zilucoplan 0·3 mg/kg once daily by self-injection, or matched placebo, for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in MG-ADL score in the modified intention-to-treat population (all randomly assigned patients who received at least one dose of study drug and had at least one post-dosing MG-ADL score). Safety was mainly assessed by the incidence of treatment-emergent adverse events (TEAEs) in all patients who had received at least one dose of zilucoplan or placebo. This trial is registered at ClinicalTrials.gov, NCT04115293. An open-label extension study is ongoing (NCT04225871)., Findings: Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo. Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004). TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group). Incidences of serious TEAEs and serious infections were similar in both groups. One patient died in each group; neither death (COVID-19 [zilucoplan] and cerebral haemorrhage [placebo]) was considered related to the study drug., Interpretation: Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being assessed in an ongoing open-label extension study., Funding: UCB Pharma., Competing Interests: Declaration of interests JFH has received research support (paid to his institution) from Alexion Pharmaceuticals, argenx BVBA, Cartesian Therapeutics, the US Centers for Disease Control and Prevention, the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the US National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB Biosciences), and Takeda Pharmaceuticals; honoraria from Alexion Pharmaceuticals, argenx BVBA, F Hoffman-LaRoche, Immunovant, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, and Viela Bio (now Horizon Therapeutics); and non-financial support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals (now UCB Biosciences), and Toleranzia. SB has served as a paid consultant for Sanofi Genzyme, Merck, Alexion, UCB, Biogen, and Bristol Myers Squibb. AG has served as a paid consultant for Medtronic, Atlantic Research Group, Calico, Apellis, Anexon, ALS Pharmaceuticals, QurAlis, Orion, Sanofi Genzyme, Ionis, Wave Life Therapies, Anelixis, Roche, Cytokinetics, Mitsubishi Tanabe Pharma, Amylyx, Alexion, UCB, Ra Pharmaceuticals (now UCB Biosciences), Biogen, Eli Lilly, and Amicus Therapeutics. CH has received funding for consultancy on scientific or educational advisory boards for UCB Pharma, argenx, Lupin, Roche and Biogen. HJK is a consultant for Roche, Cabaletta Bio, Lincoln Therapeutics, Takeda, and UCB Pharmaceuticals; and is chief executive officer and chief marketing office of ARC Biotechnology, based on US Patent 8,961,98. He is principal investigator of the Rare Disease Network for Myasthenia Gravis National Institute of Neurological Disorders & Stroke, and Targeted Therapy for Myasthenia Gravis. AM received funding for travel, meeting attendance, or advisory board participation from CSL Behring and UCB. RM received funding for travel, meeting attendance, or advisory board participation from Alexion, argenx, BioMarin, Catalyst, Sanofi, Regeneron, and UCB. MM has served as a paid consultant for argenx and Alexion Pharmaceuticals, and has received speaker honoraria from Asahi Kasei Medical, argenx and Alexion Pharmaceuticals. KU has served as a paid consultant for UCB Pharma, argenx, Janssen Pharma, Viela Bio, Chugai Pharma, Hanall BioPharma, and Mitsubishi Tanabe Pharma; and has received speaker honoraria from argenx, Alexion Pharmaceuticals, and the Japan Blood Products Organization. TV is the USF Site Principal Investigator for myasthenia gravis clinical trials sponsored by Alexion/AstraZeneca, argenx, Ra/UCB, Horizon/Viela Bio, Janssen/Momenta, Sanofi, Regeneron, and Cartesian Therapeutics; and has received speaking or consulting honoraria from Alexion, argenx, and UCB. MDW has received honoraria for serving on scientific advisory boards for Alexion, UCB-Ra, argenx, Biogen, Mitsubishi Tanabe Pharma, and Amylyx; consulting honoraria from Cytokinetics and CSL Behring; and speaker honoraria from Soleo Health. He also serves as a special government employee for the US Food and Drug Administration. MZ has served as a paid consultant for Signant Health. MZ was an employee of Medical University of Warsaw, Warsaw, Poland, during the conduct of the study, but is currently employed by MTZ Clinical Research powered by Pratia. BB, Melissa Brock, GdlB, PWD, and MV are employees and shareholders of UCB Pharma. RL was a Veramed consultant for UCB Pharma during the conduct of the study. Veramed are a full-service provider for UCB Pharma. RL is employed by ONO Pharma UK. MIL is funded by the UK National Health Service (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, Oxford, UK. She has been awarded research grants from the UK association for patients with myasthenia, Myaware, and the University of Oxford. She has received speaker honoraria or travel grants from Biogen Idec, Novartis, argenx, UCB, and the Guthy-Jackson Charitable Foundation. MIL serves on scientific or educational advisory boards for UCB Pharma, argenx, and Viela/Horizon. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Published
2023
Full Text
View/download PDF

15. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.

Author

Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, Pinal-Fernandez I, Allenbach Y, Boroojerdi B, Vanderkelen M, Delicha EM, Koendgen H, Farzaneh-Far R, Duda PW, Sayegh C, and Benveniste O

Abstract

Background: Immune-mediated necrotizing myopathy (IMNM) is an autoimmune myopathy characterised by proximal muscle weakness, high creatine kinase (CK) values, and autoantibodies recognizing 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) or the signal recognition particle (SRP). There are currently no approved therapies for IMNM and many patients experience active disease despite off-label treatment with intravenous immunoglobulin, glucocorticoids, and immunosuppressants. Detection of complement-activating anti-HMGCR and anti-SRP autoantibodies and the presence of complement deposition on the sarcolemma of non-necrotic myofibers led to the hypothesis that complement activation may be pathogenic in IMNM, therefore zilucoplan, a complement component 5 (C5) inhibitor, could be a potential therapy., Methods: IMNM01, a phase 2, multicenter, randomised, double-blind, placebo-controlled study (NCT04025632) at 15 sites (four countries) evaluated efficacy, safety, and tolerability of zilucoplan in adult participants with anti-HMGCR or anti-SRP autoantibody-positive IMNM. Participants were randomised 1:1 to receive daily subcutaneous zilucoplan (0·3mg/kg) or placebo for eight weeks; with optional enrolment in the study open-label extension. Primary efficacy endpoint was percent change from baseline to Week 8 in CK levels. Secondary endpoints included safety., Findings: Between 07 November 2019 and 07 January 2021, 27 participants (13 female and 14 male) received zilucoplan (n=12) or placebo (n=15) and completed the 8-week main study. At Week 8 there were no clinically relevant or statistically significant differences, despite target engagement based on mode of action, between treatment arms in mean percent change (standard deviation) of CK levels versus baseline (-9·86% [26·06] versus -20·72% [31·22] in zilucoplan [n=10] and placebo arms [n=14], p=0·46, respectively) and no clinically relevant improvement over time within the treatment arm. There were no unexpected adverse safety or tolerability findings. Treatment emergent adverse events (TEAEs) and serious TEAEs were reported in n=9 (75·0%) vs n=13 (86·7%) and n=0 (0%) and n=3 (20·0%) participants, respectively. The most frequent TEAEs were headache (n=4 in both groups [33·3% and 26·7%, respectively]) and nausea (n=3 in both groups [25·0% and 20·0%, respectively])., Interpretation: C5 inhibition does not appear to be an effective treatment modality for IMNM. Rather than driving myofiber necrosis, complement activation may be secondary to muscle injury., Funding: Study funded by Ra Pharmaceuticals (now part of UCB Pharma)., Competing Interests: Declaration of interests ALM is a patent author for the anti-HMGCR test. AAA has participated in medical advisory boards/acted as a consultant for Argenx, Ra Pharmaceuticals, Alexion, EMD Serono, OnoPharma, Horizon Therapeutics, Takeda, Johnson & Johnson (COVID-19 vaccination program) MD has served or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Medlink, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma, and UpToDate. Dr. Dimachkie received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, UCB Biopharma / RaPharma, Viromed/Healixmith & TMA. HC has received personal compensation for activities with Novartis, UCB, Lilly, Biogen, Orphazyme, Astra Zeneca as a speaker, advisory board member or consultancy, grants via The University of Manchester from Novartis, UCB and MedImmune, and has received travel support from Abbvie and Janssen. JBL has received speakers fees, travel support, and/or consultancy fees from Sanofi Genzyme, Roche, and Biogen. Yves Allenbach: has received personal compensation for activities with Lilly, and CSL-Berhing as a speaker or consultancy. Mark Vanderkelen: Employee and stockholder of UCB Pharma Eumorphia Delicha: Contractor of UCB Pharma Ramin Farzaneh-Far: was an employee of Ra Pharma at the time of the study BB, HK, PWD, CS* and OB are employees and stockholders of UCB Pharma IPF and YH have no competing interests to declare *Employee at the time to the study

Published
2023
Full Text
View/download PDF

16. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.

Author

Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, and Yu Z

Subjects
Alendronate pharmacology, Antibodies, Monoclonal, Bone Density, Female, Femur Neck, Humans, Postmenopause, Bone Density Conservation Agents adverse effects, Fractures, Bone epidemiology, Osteoporosis drug therapy, Osteoporosis, Postmenopausal drug therapy, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic drug therapy
Abstract

Patients with osteoporosis and chronic kidney disease (CKD) are at increased risk of fracture and associated negative outcomes, including increased mortality. The present post hoc analysis of two randomized, multicenter, phase 3 clinical trials-Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) and Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH)-investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis and mild-to-moderate CKD. The analysis included data from 7147 patients from FRAME and 4077 from ARCH. Eighty-one percent of patients from FRAME and 85% from ARCH had mild or moderate reduction in estimated glomerular filtration rate (eGFR) at baseline, and part of this reduction is likely age related. During the 1-year double-blind phases of the trials, patients received romosozumab 210 mg sc or placebo monthly in FRAME and romosozumab 210 mg sc monthly or alendronate 70 mg po weekly in ARCH. Bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck and vertebral and nonvertebral fractures were assessed at baseline and month 12. In both trials, the least-square mean percent change from baseline BMD was significantly greater in the romosozumab groups versus controls across all kidney function categories at month 12. Romosozumab reduced the relative risk of new vertebral fractures at month 12 among patients with eGFR of 30-59, 60-89, and ≥90 mL/min by 72% (95% confidence interval [CI] 14-91; p = 0.017), 70% (40-85; p < 0.001), and 84% (30-96; p = 0.005), respectively, in FRAME versus placebo, and by 51% (5-75; p = 0.04), 19% (-28 to 49; p = 0.39), and 57% (1-81, p = 0.04), respectively, in ARCH versus alendronate. Incidences of adverse events, asymptomatic decreases in serum calcium, and evolution of kidney function during the studies were similar across all baseline kidney function groups. Romosozumab is an effective treatment option for postmenopausal women with osteoporosis and mild-to-moderate reduction in kidney function, with a similar safety profile across different levels of kidney function. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)., (© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).)

Published
2022
Full Text
View/download PDF

17. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.

Author

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, and Förger F

Subjects
Abnormalities, Drug-Induced epidemiology, Abnormalities, Drug-Induced etiology, Adult, Databases, Factual, Female, Humans, Infant, Newborn, Pharmacovigilance, Pregnancy, Pregnancy Outcome, Prospective Studies, Retrospective Studies, Teratogenesis, Young Adult, Antirheumatic Agents adverse effects, Certolizumab Pegol adverse effects, Maternal Exposure adverse effects, Pregnancy Complications drug therapy, Rheumatic Diseases drug therapy
Abstract

Objective: Anti-tumor necrosis factor (anti-TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti-TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF agent approved for the treatment of rheumatic diseases and/or Crohn's disease, has minimal to no active placental transfer. This analysis was undertaken to evaluate pregnancy outcomes in women receiving CZP, especially those exposed during early pregnancy., Methods: Prospective and retrospective data on maternal CZP exposure were extracted from the UCB Pharma safety database through March 6, 2017. Analysis was limited to prospective reports to avoid potential bias associated with retrospective submissions. The numbers of live births, miscarriages, elective abortions, stillbirths, and major congenital malformations were ascertained., Results: Of 1,137 prospectively reported pregnancies with maternal exposure to CZP, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%). There were 8 major congenital malformations (1.7%) among the 459 infants. First trimester exposure occurred in 367 (81.2%) of 452 pregnancies resulting in 459 live births. Exposure during all 3 trimesters occurred in 201 (44.5%) of 452 pregnancies., Conclusion: This analysis represents the largest cohort of pregnant women exposed to an anti-TNF agent for management of chronic inflammatory diseases. Analysis of pregnancy outcomes does not indicate a teratogenic effect of CZP, compared to the general population, nor an increased risk of fetal death. The data are reassuring for women of childbearing age considering treatment with CZP., (© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College ofRheumatology.)

Published
2018
Full Text
View/download PDF

18. Urinary plasma protein patterns in acute prostatitis.

Author

Everaert K, Delanghe J, Vanderkelen M, Cornelis K, De Wachter S, Viaene A, De Ruyck E, Clarysse B, and Oosterlinck W

Subjects
Acute Disease, Adult, Biomarkers urine, Cystitis diagnosis, Humans, Male, Middle Aged, Prostatitis diagnosis, Protease Inhibitors urine, Pyelonephritis diagnosis, Sensitivity and Specificity, Albumins metabolism, Alpha-Globulins urine, Cystitis urine, Prostatitis urine, Pyelonephritis urine, alpha-Macroglobulins urine
Abstract

We evaluated the diagnostic utility of urinary alpha1-microglobulin, alpha2-macroglobulin and albumin in the diagnosis of acute prostatitis. We studied 133 men (43 +/- 17 years) with, and a reference population (n=36, 41 +/- 16 years) without, urinary tract infection. Prostatectomy samples were used to study the potential interference between prostatic proteins and protein analysis. Urinary alpha2-macroglobulin/albumin ratio was significantly lower in prostatitis compared to the reference population, cystitis or acute pyelonephritis (p < 0.0001). Low alpha2-macroglobulin concentrations in prostatitis are due to inhibition (p = 0.0001) of the immune reaction between alpha2-macroglobulin in presence of polyclonal rabbit antibodies (used for immunonephelometry) by soluble prostatic proteins (+/- 60 kDa) which appear in urine in acute prostatitis. The urinary alpha1-microglobulin/creatinine ratio diagnoses acute pyelonephritis (sensitivity 100% and specificity 87%) and the urinary alpha2-macroglobulin/albumin ratio diagnoses acute prostatitis (sensitivity 100% and specificity of 90%). Stepwise multinomial logistic regression analysis reveals that urinary alpha1-microglobulin, alpha2-macroglobulin, albumin and creatinine provide optimal differentiation between acute pyelonephritis and acute prostatitis (pseudo R2=0.83; Loglikelihood -30.55, p < 0.000001). In conclusion, the combination of hematuria and absence of urinary alpha-2-macroglobulin is diagnostic for acute prostatitis. Even without hematuria, alpha2-macroglobulin remains lower compared to patients without prostatitis.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results